Earnings Troubles May Signal Larger Issues for Shanghai Haoyuan Chemexpress (SHSE:688131) Shareholders
May 06
Chinese (SSE) Clinical Research and Equipment Industry Analysis
UpdatedMay 06, 2024
DataAggregated Company Financials
Companies24
- 7D2.6%
- 3M6.3%
- 1Y-34.9%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has risen 6.2%, driven by gains in MGI Tech and WuXi AppTec of 11% and 1.7%, respectively. In the same time, Joinn Laboratories(China)Co.Ltd was down 5.6%. However, the industry is down 36% over the past year. As for the next few years, earnings are expected to grow by 30% per annum.
Industry Valuation and Performance
Has the Chinese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 06 May 2024 | CN¥327.0b | CN¥89.0b | CN¥13.5b | 30.1x | 24.2x | 3.7x |
| Wed, 03 Apr 2024 | CN¥339.8b | CN¥90.3b | CN¥15.0b | 33.8x | 22.6x | 3.8x |
| Fri, 01 Mar 2024 | CN¥363.2b | CN¥90.5b | CN¥15.5b | 32.1x | 23.4x | 4x |
| Sun, 28 Jan 2024 | CN¥404.4b | CN¥91.1b | CN¥16.1b | 33.7x | 25.1x | 4.4x |
| Tue, 26 Dec 2023 | CN¥472.1b | CN¥91.1b | CN¥16.1b | 36.2x | 29.4x | 5.2x |
| Thu, 23 Nov 2023 | CN¥538.4b | CN¥91.1b | CN¥16.1b | 37.5x | 33.5x | 5.9x |
| Sat, 21 Oct 2023 | CN¥511.7b | CN¥92.2b | CN¥18.4b | 33.4x | 27.8x | 5.5x |
| Mon, 18 Sep 2023 | CN¥488.8b | CN¥92.0b | CN¥18.3b | 32.5x | 26.7x | 5.3x |
| Wed, 16 Aug 2023 | CN¥495.9b | CN¥91.6b | CN¥18.6b | 34.8x | 26.7x | 5.4x |
| Fri, 14 Jul 2023 | CN¥468.2b | CN¥91.3b | CN¥18.5b | 35.2x | 25.3x | 5.1x |
| Sun, 11 Jun 2023 | CN¥483.7b | CN¥91.3b | CN¥18.5b | 36.6x | 26.2x | 5.3x |
| Tue, 09 May 2023 | CN¥509.5b | CN¥91.5b | CN¥18.5b | 40.2x | 27.5x | 5.6x |
| Thu, 06 Apr 2023 | CN¥555.4b | CN¥90.1b | CN¥19.2b | 52x | 29x | 6.2x |
| Sat, 04 Mar 2023 | CN¥613.3b | CN¥85.5b | CN¥20.0b | 52x | 30.7x | 7.2x |
| Mon, 30 Jan 2023 | CN¥715.1b | CN¥86.6b | CN¥20.8b | 60.6x | 34.4x | 8.3x |
| Wed, 28 Dec 2022 | CN¥589.6b | CN¥86.6b | CN¥20.8b | 49.5x | 28.3x | 6.8x |
| Fri, 25 Nov 2022 | CN¥609.2b | CN¥86.6b | CN¥20.8b | 52x | 29.3x | 7x |
| Sun, 23 Oct 2022 | CN¥559.2b | CN¥78.3b | CN¥18.6b | 47.8x | 30.1x | 7.1x |
| Tue, 20 Sep 2022 | CN¥547.5b | CN¥77.8b | CN¥17.0b | 44.8x | 32.2x | 7x |
| Thu, 18 Aug 2022 | CN¥634.8b | CN¥73.4b | CN¥17.1b | 61.7x | 37.1x | 8.7x |
| Sat, 16 Jul 2022 | CN¥711.1b | CN¥69.0b | CN¥15.2b | 70.8x | 46.8x | 10.3x |
| Mon, 13 Jun 2022 | CN¥649.6b | CN¥69.0b | CN¥15.2b | 63.8x | 42.8x | 9.4x |
| Wed, 11 May 2022 | CN¥583.1b | CN¥68.2b | CN¥15.1b | 56.2x | 38.5x | 8.6x |
| Fri, 08 Apr 2022 | CN¥648.6b | CN¥62.5b | CN¥15.0b | 63.2x | 43.4x | 10.4x |
| Sun, 06 Mar 2022 | CN¥624.5b | CN¥60.9b | CN¥14.0b | 68.4x | 44.5x | 10.3x |
| Tue, 01 Feb 2022 | CN¥625.4b | CN¥57.5b | CN¥12.3b | 67.6x | 50.8x | 10.9x |
| Thu, 30 Dec 2021 | CN¥736.6b | CN¥57.2b | CN¥12.2b | 84.9x | 60.2x | 12.9x |
| Sat, 27 Nov 2021 | CN¥875.8b | CN¥56.9b | CN¥12.1b | 97.9x | 72.1x | 15.4x |
| Mon, 25 Oct 2021 | CN¥885.5b | CN¥53.9b | CN¥11.7b | 105.6x | 75.6x | 16.4x |
| Wed, 22 Sep 2021 | CN¥1.0t | CN¥55.1b | CN¥12.7b | 105.5x | 79x | 18.3x |
| Fri, 20 Aug 2021 | CN¥847.0b | CN¥55.1b | CN¥12.7b | 92.4x | 66.5x | 15.4x |
| Fri, 04 Jun 2021 | CN¥856.8b | CN¥46.5b | CN¥10.6b | 93.7x | 81.1x | 18.4x |
Price to Earnings Ratio
81.1x
Current Industry PE
- Investors are pessimistic on the Chinese Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 24.1x which is lower than its 3-year average PE of 41.2x.
- The 3-year average PS ratio of 8.9x is higher than the industry's current PS ratio of 3.7x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have grown 8.7% per year over the last three years.
- Revenues for these companies have grown 24% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Comparison
How does Chinese Clinical Research and Equipment compare with similar industries?
| CN Market | 1.22% | |
| Healthcare | 2.68% | |
| Life Sciences | 2.63% | |
| Clinical Research and Equipment | 2.63% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 603259 WuXi AppTec | CN¥45.78 | 2.7% +CN¥3.5b | -32.4% | PE14.2x | |
| 300347 Hangzhou Tigermed Consulting | CN¥61.75 | 3.5% +CN¥1.8b | -31.6% | PE31.6x | |
| 300759 Pharmaron Beijing | CN¥20.42 | 2.4% +CN¥840.1m | -36.3% | PE24.6x | |
| 300463 Maccura BiotechnologyLtd | CN¥13.62 | 5.3% +CN¥418.7m | -15.6% | PE26.1x | |
| 688315 Novogene | CN¥14.85 | 5.1% +CN¥297.3m | -55.1% | PE33.5x |
